id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dpc-2698	Bassi, Andrea; Piccolo, Vincenzo; Ginori, Alessandro; Gallippi, Grazia; Mazzatenta, Carlo	Eosinophilic Annular Erythema Due to Certolizumab Pegol Therapy for Rheumatoid Arthritis Post-COVID-19 Vaccine 	2023	3	.pdf	application/pdf	1069	88	49	2023;13(2):e2023095 1 Eosinophilic Annular Erythema due to Certolizumab Pegol Therapy for Rheumatoid Arthritis Post-COVID-19 Vaccine Andrea Bassi1, Vincenzo Piccolo2, Alessandro Ginori3, Grazia Galippi3, Carlo Mazzatenta1 1 Division of Dermatology, Azienda USL Toscana Nord Ovest, Lucca, Italy 2 Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy 3 Pathology Unit, “Monterosso Polyspecialistic Center”, Azienda USL Toscana Nord Ovest, Lucca, Italy Key words: Eosinophilic annular erythema, certolizumab pegol, adverse drug reaction, COVID-19 Citation: Bassi A, Piccolo V, Ginori A, Galippi G, Mazzatenta C. Eosinophilic Annular Erythema Due to Certolizumab Pegol Therapy for Rheumatoid Arthritis Post-COVID-19 Vaccine. Clinical differential diagnosis is with other figurate erythema such as: Wells syndrome, erythema chronicum migrans, erythema annulare centrifugum, erythema gyratum repens, annular granuloma, subacute cutaneous lupus erythema- tosus and dermatosis of the pemphigoid group	cache/dpc-2698.pdf	txt/dpc-2698.txt